This trial was registered at ClinicalTrials.gov (NCT05102305, Registration Date: 20-October-2021)
This approach reflects the FDA's commitment to balancing medication access with patient safety
The discussion drew on over a decade of Virtas experience prescribing, managing, and deprescribing GLP-1s and covered everything from long-term efficacy and deprescription to benefit design, cost management, and the future of GLP-1 access
The Journal of Clinical Endocrinology & Metabolism, 91 (3), 799-805.
However, in an online survey conducted between December 2021 and February 2023, 56.5% of the 470 respondents recruited through advertisements on websites related to AAS use reported PCT use when stopping AAS (Grant et al., 2023b)
The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial